ClaimsPeople

Jeremy Grantham

Jeremy Grantham is an investor who co-founded the asset managers GMO and Batterymarch, is listed by GMO as its long-term investment strategist, and co-authored 'The Making of a Permabear'.

1,004 claims collected, 267 researched, 73 resolved. Report of 5 November 2026, method 0.1.0+28da144b.

Scores by kind of claim

Each kind of claim is scored on its own, out of 100: the share that held up, with the range it likely falls in. Fewer resolved claims give a wider range.

  • Factual claims

    Statements about the present or the past, checked against the record: did they hold up?

    72 63 80

    Medium confidence, 42 factual claims resolved. From 15 documents, 2007 to 2025; 15 documents sampled from 32 candidates found.

    Not scored: 53 unresolvable, 28 checkable only against their own records.

  • Predictions

    Statements about events outside the person's control, checked once they fell due: did they come true?

    56 46 67

    Medium confidence, 31 predictions resolved. From 10 documents, 2007 to 2023; 15 documents sampled from 32 candidates found.

    Not scored: 93 unresolvable, 1 checkable only against their own records. 17 more fall due later.

    Does not yet allow for how likely each prediction was when made.

  • Promises

    Commitments to the person's or organisation's own future action, with something to deliver: was it delivered?

    Insufficient record: 0 promises resolved, 5 needed for a score.

    Not scored: 2 unresolvable.

All types combined: 65 (likely 59 to 72, high confidence), from 73 claims: 42 factual claims, 31 predictions. It mixes kinds of claim in different proportions for different people, so compare people kind by kind.

Jeremy Grantham's claims

1,004 claims, sorted by newest said. Choose a claim to read it in full.
VerdictKindSaidClaimTopic
Not researched Factual Apr 2007 Several academics think leveraged buyouts are a modest destroyer of real value. Factual · Apr 2007 Economics and markets
Unresolvable Prediction Apr 2007 U.S. blue chips and U.S. bonds will mostly be priced lower relative to fair value than the trendier newer asset classes. Prediction · Apr 2007 Economics and markets
Not checkable Not checkable Apr 2007 If you believed this data you should, of course, put all your money in cash. Not checkable · Apr 2007
Not checkable Not checkable Apr 2007 This was a ridiculously high real return for an asset whose virtues included that it was exceptionally diversifying Not checkable · Apr 2007
Back to the list

Prediction Economics and markets

“Conversely, the sources of funds – U.S. blue chips and U.S. bonds – will be in the reverse position and will mostly be lower priced relative to fair value than the trendier ‘newer asset classes.’”

Jeremy Grantham, GMO letter author April 2007 The First Truly Global Bubble (It's Everywhere, In Everything) (GMO)

U.S. blue chips and U.S. bonds will mostly be priced lower relative to fair value than the trendier newer asset classes.

Unresolvable The public record could not settle it.

Said for an organisation they lead or work for; it counts on both records.

What would count as true or false

Test: in the period after April 2007 that Grantham was describing (the late stage of the 2007 credit/risk boom, roughly mid-2007 to 2008), were U.S. blue chips (large high-quality U.S. stocks) and U.S. bonds priced lower relative to fair value (cheaper, with higher expected returns) than the trendier 'newer asset classes' (e.g. emerging market equities, private equity, commodities, hedge-fund-type and other risky alternative assets)? True: GMO's own valuation measures (e.g. its seven-year asset class forecasts) or comparable independent valuation evidence from that period show U.S. blue chips and U.S. bonds as relatively cheaper than most of those newer asset classes. Mostly true: this holds for most of those comparisons with a minor exception. Mixed: it holds for one of the two (blue chips or bonds) but not the other, or for about half of the newer asset classes. Mostly false: the gap was negligible or held only for a small minority of comparisons. False: the evidence shows U.S. blue chips and U.S. bonds were valued the same as or more richly relative to fair value than the newer asset classes.

Evidence

  1. Opportunity lying in plain sight The Motley Fool Australia · 18 October 2011
    “As of the end of last month, GMO liked high-quality U.S. stocks and international stocks as well. It predicted 7.2% real annual returns for international large caps and emerging markets. U.S. high-quality stocks are forecast to produce returns in the neighborhood of 6.6%.”
  2. Opportunity lying in plain sight The Motley Fool Australia · 18 October 2011
    “The firm also forecast a negative 1% return for the S&P 500 during the period. It returned essentially nothing over that 10-year stretch.”
  3. Opportunity lying in plain sight The Motley Fool Australia · 18 October 2011
    “As of the end of last month, GMO liked high-quality U.S. stocks and international stocks as well. It predicted 7.2% real annual returns for international large caps and emerging markets. U.S. high-quality stocks are forecast to produce returns in the neighborhood of 6.6%.”
  4. Jeremy Grantham: Stocks Still Aren't Cheap Seeking Alpha · 12 October 2008
    “True, fair value on the S&P 500 is about 1,025 - vs. last week's close of about 900 - but bubbles tend to overcorrect by more than that (20%).”
  5. Jeremy Grantham: Stocks Still Aren't Cheap Seeking Alpha · 12 October 2008
    “One bet that he continues to like is to go long high-quality, blue-chip stocks - and short risky companies.”
  6. Jeremy Grantham: Stocks Still Aren't Cheap Seeking Alpha · 12 October 2008
    “He will at some point look to move slowly back into the cheapest pockets of emerging-market equities and small-cap international value - which are down 50% and 40% respectively since late last year.”

Reasoning

E5 (October 2008) reports that Grantham still favoured going long high-quality blue chips and short risky companies. E6 says emerging-market equities had fallen 50% since late 2007. Both point loosely toward blue chips being relatively favoured, but neither gives a comparative valuation of blue chips against the newer asset classes for mid-2007 to 2008. None of the evidence covers U.S. bonds. E1 and E3 describe GMO forecasts from 2011, which is outside the period being tested; E2 describes an earlier S&P 500 forecast over an unspecified ten-year stretch; and E4 gives only an S&P 500 fair-value estimate. That is not enough to settle the comparison the criteria require.

Cite this claim

Jeremy Grantham, “U.S. blue chips and U.S. bonds will mostly be priced lower relative to fair value than the trendier newer asset classes.” (said April 2007). Verdict: unresolvable. Reliability API, claim c_f6fb4daea5ae, method 0.1.0+28da144b. https://epistacklabs.com/claims/c_f6fb4daea5ae

Claims without a verdict

Is a verdict here wrong, or do you speak for Jeremy Grantham? Reply on the claim's own page, with the form at its foot (how replies work). Verdicts are made automatically; how verdicts and scores are made.